RT Journal Article
SR Electronic
T1 Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 1801298
DO 10.1183/13993003.01298-2018
VO 53
IS 2
A1 Cubillos-Zapata, Carolina
A1 Martínez-García, Miguel Ángel
A1 Campos-Rodríguez, Francisco
A1 Sánchez de la Torre, Manuel
A1 Nagore, Eduardo
A1 Martorell-Calatayud, Antonio
A1 Hernández Blasco, Luis
A1 Chiner Vives, Eusebi
A1 Abad-Capa, Jorge
A1 Montserrat, Josep María
A1 Cabriada-Nuño, Valentín
A1 Cano-Pumarega, Irene
A1 Corral-Peñafiel, Jaime
A1 Diaz-Cambriles, Trinidad
A1 Mediano, Olga
A1 Somoza-González, María
A1 Dalmau-Arias, Joan
A1 Almendros, Isaac
A1 Farré, Ramón
A1 López-Collazo, Eduardo
A1 Gozal, David
A1 García-Río, Francisco
YR 2019
UL http://erj.ersjournals.com/content/53/2/1801298.abstract
AB Obstructive sleep apnoea (OSA) upregulates the programmed cell death-1 receptor and its ligand (PD-L1) pathway, potentially compromising immunosurveillance. We compared circulating levels of soluble PD-L1 (sPD-L1) in patients with cutaneous melanoma according to the presence and severity of OSA, and evaluated relationships with tumour aggressiveness and invasiveness.In a multicentre observational study, 360 patients with cutaneous melanoma underwent sleep studies, and serum sPD-L1 levels were assayed using ELISA. Cutaneous melanoma aggressiveness indices included mitotic rate, Breslow index, tumour ulceration, Clark level and tumour stage, and sentinel lymph node (SLN) metastasis was recorded as a marker of invasiveness.sPD-L1 levels were higher in severe OSA compared to mild OSA or non-OSA patients. In OSA patients, sPD-L1 levels correlated with Breslow index and were higher in patients with tumour ulceration, advanced primary tumour stages or with locoregional disease. The incorporation of sPD-L1 to the classic risk factors to SLN metastasis led to net improvements in the classification of 27.3%.Thus, sPD-L1 levels are increased in melanoma patients with severe OSA, and, in addition, might serve as a potential biomarker of cutaneous melanoma aggressiveness and invasiveness in this group of subjects.In patients with cutaneous melanoma, severe OSA increases serum levels of sPD-L1, which are associated with several indices of tumour aggressiveness and are an independent risk factor of sentinel lymph node metastasis http://ow.ly/qAU030mC7xx